explore -WSS

explore

author：entertainment 2025-09-08 19:22:28 - browse：46

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Annovis Bio delivers candor, but not confidence, on Parkinson’s study

explore

WSS

PBM reform efforts get punted in Congress

Stigma and the return of syphilis

PBM reform efforts get punted in Congress

Prosthetic arm enables patients to feel the objects they grip

Alabama frozen embryo ruling has major implications for IVF clinics

Akili, maker of video game for ADHD, to be acquired for 34 million

hotspot

explore

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

AI used to predict Covid

Malaria cases in Florida and Texas: Here’s what you need to know

Dark money group runs ads on China biotech bill

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Focused ultrasound for uterine fibroids: an uphill battle

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

iTeos Therapeutics debuts first data on TIGIT

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

hotspot

PBM reform efforts get punted in Congress

Medicare inequities exacerbate Puerto Rico’s health disparities

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

iTeos Therapeutics debuts first data on TIGIT

Heat waves linked to early deliveries, preterm births in new study

leisure time

explore

Wikipedia

hotspot